rotation.to
Following this device: dark.
Free account
rotation.to
Sign in / Request free access
Appearance
Following this device: dark.
Drag a card by its title · ⚙ to size, swap or remove

The company

Viking Therapeutics, Inc.

VKTX · Nasdaq

Health CareBiotechnologyNot moving yetGLP-1

VKTX stood above a rising 150-day average in 21 of the last 52 weekly readings, and has been out of that trend for the last 6 weeks. It is 24.0% below that average now. Biotechnology: 16% of its 561 stocks in an uptrend (−15 points in four weeks); Health Care: 26% (−10 points in four weeks).

SEC filings

Statistics

Rotation
Not moving yet
Weeks in an uptrend
out for 6
Industry in uptrend
16% -15 in 4 wk
Insider buys, 12 months
$300K
Insider sales, 12 months
$40.6M
Officials’ trades on record
0
Institutions holding
405 (+17)

In the rotation

Each square a week: lit when it closed above a rising 150-day average. 21 of 52 weeks.

20 Apr – 19 Oct
17%28%39%Apr 26Jun 26Jul 26Sep 26Oct 26

Biotechnology: Few of its stocks are in an uptrend and the share has fallen sharply over four weeks. Health Care: A minority of its stocks are in an uptrend and the share has fallen sharply over four weeks.

Money in and out

1 Nov 2024 – 1 Oct 2026
−$23.2M$0Nov 24May 25Nov 25Apr 26Oct 26

Open-market buys above the line and sales below, in dollars.

Congress and officials

No member of Congress or official has disclosed a trade in it.

Insiders

Buy orders, 12 months1
Sale orders, 12 months11
Buyers · sellers1 · 5
WhoDidSharesTraded
Marianna ManciniChief Operating Officersold18,217at $33.4729 Jul 2026filed 29 Jul 2026
Greg ZanteChief Financial Officersold21,217at $33.4729 Jul 2026filed 29 Jul 2026
Brian LianPresident & CEOsold148,517at $33.3229 Jul 2026filed 29 Jul 2026
Neil William AubuchonChief Commercial Officerbought4,475at $33.5010 Mar 2026filed 10 Mar 2026
Brian LianPresident & CEOsold132,454at $32.295 Jan 2026filed 5 Jan 2026
Brian LianPresident & CEOsold53,279at $33.385 Jan 2026filed 5 Jan 2026
Brian LianPresident & CEOsold41,276at $34.225 Jan 2026filed 5 Jan 2026
Brian LianPresident & CEOsold6,400at $35.075 Jan 2026filed 5 Jan 2026
Marianna ManciniChief Operating Officersold31,961at $32.295 Jan 2026filed 5 Jan 2026
Marianna ManciniChief Operating Officersold13,600at $33.375 Jan 2026filed 5 Jan 2026
Marianna ManciniChief Operating Officersold10,500at $34.225 Jan 2026filed 5 Jan 2026
Marianna ManciniChief Operating Officersold1,600at $35.075 Jan 2026filed 5 Jan 2026

Lines filed since 2 January 2026, newest first; every insider’s older lines are on their own page.

Institutions

Holders405+17 on the quarter
New · exited71 · 53
Reported value$3.0B

Quarter to 30 Jun 2026, against 31 Mar 2026; newest filing 31 Aug 2026.

ManagerSharesChange
FMR LLCadded · filed 13 Aug 20266,335,756$247.2M+311,003+5.2%
BlackRock, Inc.reduced · filed 7 Aug 20266,189,649$241.5M-690,641−10.0%
STATE STREET CORPadded · filed 7 Aug 20265,606,394$218.7M+1,210,837+27.5%
VANGUARD CAPITAL MANAGEMENT LLCadded · filed 13 Aug 20265,053,663$197.1M+41,161+0.8%
VANGUARD PORTFOLIO MANAGEMENT LLCadded · filed 13 Aug 20264,484,263$174.9M+19,965+0.4%
TWO SIGMA INVESTMENTS, LPreduced · filed 14 Aug 20263,937,414$153.6M-494,728−11.2%
MORGAN STANLEYadded · filed 13 Aug 20263,486,040$136.0M+472,112+15.7%
AMERIPRISE FINANCIAL INCadded · filed 14 Aug 20262,156,083$84.1M+477,338+28.4%
GEODE CAPITAL MANAGEMENT, LLCadded · filed 12 Aug 20262,097,981$81.9M+15,914+0.8%
AMERICAN CENTURY COMPANIES INCreduced · filed 12 Aug 20261,816,050$70.8M-262,527−12.6%
31 Mar 2023 – 30 Jun 2026
163280396Mar 23Dec 23Dec 24Sep 25Jun 26

News

Viking Therapeutics Just Raised $575 Million. Here's What It Means for the Obesity Stock's Next Chapter.fool.com · 18 Oct 2026Oppenheimer Thinks Viking Therapeutics Stock Can Soar to $120. Here's the Math Behind the Ultra-Bullish Call.fool.com · 12 Oct 2026Oppenheimer Thinks Viking Therapeutics Stock Can Soar to $120. Here's the Math Behind the Ultra-Bullish Call.fool.com · 12 Oct 2026Viking Therapeutics' Oral Obesity Drug Advances to Phase 3 Testing. Is Now the Time to Buy This Biotech Stock?fool.com · 10 Oct 2026Viking Therapeutics Launches Phase 2 Oral VK2735 Maintenance Studyfinanzen.ch · 6 Oct 2026Should You Buy Viking Therapeutics Stock While It Trades Below Its $35 Offering Price?aol.com · 2 Oct 2026Viking Therapeutics Stock Soars 36% on Weight-Loss Drug Data. Why It's Not Too Late to Buy the Stock.fool.com · 30 Sep 2026Eli Lilly Stock Barely Moved Following Viking Therapeutics' Impressive Clinical Results. Here's Why.aol.com · 29 Sep 2026

Everyone who traded it

Dorothy Elizabeth Kelly-Gemmell Company insiderDirector · last 1 Aug 20260 · 0
Brian Lian Company insiderPresident & CEO · last 29 Jul 20260 · 20
Greg Zante Company insiderChief Financial Officer · last 29 Jul 20260 · 14
Marianna Mancini Company insiderChief Operating Officer · last 29 Jul 20260 · 10
Hubert C. Chen Company insiderChief Medical Officer · last 1 Jun 20260 · 0
Neil William Aubuchon Company insiderChief Commercial Officer · last 10 Mar 20261 · 0
Charles A. Rowland Jr. Company insiderDirector · last 2 Jan 20261 · 2
J. Matthew Singleton Company insiderDirector · last 2 Jan 20261 · 5
Lawson Macartney Company insiderDirector · last 2 Jan 20261 · 4
Matthew W. Foehr Company insiderDirector · last 2 Jan 20265 · 2
Sarah Kathryn Rouan Company insiderDirector · last 2 Jan 20262 · 3
Michael Morneau Company insiderVP, Finance and Administration · last 19 Jan 20210 · 1

Same industry

MRNA ModernaLeading+154%
IOVA Iovance BiotherapeuticsLeading+133%
ABCL AbCellera BiologicsLeading+61%
ENTX Entera BioLeading+49%
HALO Halozyme TherapeuticsLeading+46%
XERS Xeris Biopharma HoldingsLeading+46%
HELP Helus PharmaLeading+37%
XNCR XencorLeading+32%

Distance from each stock’s own 150-day average.

Government contracts

No federal award is tied to it.

From its SEC filings

Return on capital employedFY 2025 · to 31 Dec 2025-61.5%
Share count trendFY 2025 · to 31 Jan 20260.7%
Cash and equivalentsFY 2025 · to 31 Dec 2025$165.8M

Analyst forecasts

No analyst forecasts yet.